ABL1 and Parkinson disease: Moreover, it displays invitro activity against numerous Imatinib-resistant mutants.4,5 Besides all these, some research found that Parkinson’s disease(PD) models and patient brain tissues had higher levels of cellularAbelson (c-Abl) activation.6−8 In animal models of neurodegeneration,low doses of nilotinib promote the degradation of tau and Aβby crossing the blood–brain barrier.